Veradermics, Incorporated (MANE) Balance Sheet
As of 2026-06-30 (10-Q), Veradermics, Incorporated (MANE) reported total assets of $825.7M, total liabilities of $12.1M and shareholders' equity of $813.6M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $319.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MANEVeradermics, IncorporatedFollow MANE — free
—
Price chart with a free account
- Market cap
- 5.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|
| Cash and equivalents | 53.1 | 21.8 | 319.3 | |
| Short-term investments | 0.0 | 120.1 | 500.6 | |
| Current assets | 55.5 | 152.5 | 824.7 | |
| Total assets | 55.5 | 152.6 | 825.7 | |
| Current liabilities | 4.7 | 9.2 | 11.7 | |
| Total liabilities | 4.7 | 9.2 | 12.1 | |
| Shareholders' equity | -48.5 | -121.0 | 813.6 |
USD millions · SEC XBRL
Veradermics, Incorporated — questions
- How much cash does Veradermics, Incorporated have?
- $319.3M in cash and cash equivalents as of 2026-06-30.
- What are Veradermics, Incorporated's total assets?
- $825.7M as of 2026-06-30.
- What is Veradermics, Incorporated's shareholders' equity?
- $813.6M as of 2026-06-30.
Every figure on this page comes from Veradermics, Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.